Stock REVO BIOLOGICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Revo Biologics Inc Stock

Equities

US76155H1059

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Revo Biologics Inc

Press releases Revo Biologics Inc

Revo Biologics : LFB S.A. Receives Go Ahead From Data Monitoring Committee to Expand The Global PERSEPT Phase 3 Program of LR769 in Hemophilia A or B Patients with Inhibitors BU
More press releases

News in other languages on Revo Biologics Inc

Revo Biologics : LFB S.A. reçoit le feu vert du Comité de surveillance et de suivi pour étendre le programme de phase III PERSEPT sur le LR769 dans le traitement des patients atteints d'hémophilie A ou B associée à la présence d'inhibiteurs
Revo Biologics : Datenüberwachungskomitee gibt LFB S.A. das grüne Licht für den Ausbau des multinationalen PERSEPT-Phase-3-Programms für LR769 bei Patienten mit Hämophilie A oder B, die Hemmstoffe entwickelt haben
More news

Company Profile

More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. Stock